HeartBeam, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2021. This is an annual report; the filing does not provide standalone fourth-quarter results. HeartBeam is a pre-revenue medical technology company developing cardiac monitoring and diagnostic products. Its products had not received FDA marketing clearance as of the filing.
Financial performance and position
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | No revenue reported | No revenue reported |
| General and administrative expense | $2.030 million | $0.655 million |
| Research and development expense | $0.255 million | $0.133 million |
| Operating loss | $2.285 million | $0.788 million |
| Interest expense | $2.165 million | $0.280 million |
| Net loss | $4.428 million | $1.068 million |
| Net loss per share, basic and diluted | $1.03 | $0.29 |
| Cash and cash equivalents at year-end | $13.192 million | $0.024 million |
| Net cash used in operating activities | $3.230 million | $0.600 million |
Margins are not meaningful because the company reported no revenue. Total assets were $13.998 million, total liabilities $0.588 million, and stockholders’ equity $13.410 million at December 31, 2021. There was no convertible-note balance at year-end: principal and accrued interest totaling approximately $6.288 million converted into 1,497,216 common shares when the IPO closed. The company reported no off-balance-sheet arrangements.
Material changes versus 2020
- Net loss increased by $3.360 million, principally reflecting higher operating expenses and interest expense.
- General and administrative expense rose 210% to $2.030 million, including higher personnel costs and public-company, investor-relations, board, and SEC-reporting expenses.
- Research and development expense increased 92% to $0.255 million as work continued on the telehealth system and began on the emergency-department software product.
- Interest expense increased by $1.885 million, mainly from accretion of the 30% discount on the 2015 convertible notes.
- The November 2021 IPO generated approximately $14.713 million in net proceeds. Together with $1.715 million raised through convertible notes, it contributed to $16.398 million of financing cash flow.
Business, outlook, and risks
HeartBeam is developing a credit-card-sized, three-lead ECG device and cloud-based software for remote cardiac monitoring, as well as software intended to improve heart-attack detection in emergency departments. The company reported three clinical studies, including encouraging results in small study populations, but these results do not establish regulatory clearance or commercial effectiveness. Its business depends on completing product development, obtaining FDA clearance, securing reimbursement, and achieving physician and customer adoption.
Management stated that cash on hand was expected to fund operations for the next 12 months based on its business-plan assumptions and anticipated cash burn. The filing also says continued operations depend on obtaining additional capital or strategic relationships; future financing may be unavailable or dilutive. In February 2022, the company raised a further $348,000 in a private placement.
Management’s stated plans included submitting the ED product for FDA 510(k) review in 2022 and the telehealth product later in 2022, with telehealth clearance expected in early 2023. The filing gives differing ED timing descriptions: it refers to a planned second-quarter 2022 submission in some sections and expected third-quarter 2022 clearance in a financial-statement note. These are forward-looking plans, not achieved milestones. Subsequent to year-end, HeartBeam entered into development agreements with LIVMOR and Triple Ring; the filing cites approximately $3.0 million of 2022 commitments, with about $1.4 million made by the filing date, plus future platform license fees.
- Key risks: FDA review or classification could delay or prevent commercialization; clinical findings may not be replicated; reimbursement and market acceptance are uncertain; and the company has limited operating history, no product revenue, and ongoing funding needs.
- Execution and operating risks: dependence on third-party developers, manufacturers, suppliers, wireless and cloud services; product quality, cybersecurity, privacy, and product-liability exposure; competition from larger companies; and risks to the Serbia-based R&D team from geopolitical developments.
- Controls: management identified material weaknesses in internal control over financial reporting, including inadequate documentation and approval/review procedures, insufficient GAAP expertise for complex reporting, and insufficient staffing for segregation of duties and oversight. The auditor did not attest to internal-control effectiveness.
- Other items: the filing reports no material pending legal proceedings. HeartBeam had five full-time employees at year-end 2021.
Important facts for investors to verify
- Whether the reported cash balance and management’s 12-month runway remain adequate after operating costs, development commitments, and other cash needs.
- Actual FDA submission and clearance status for each product, including resolution of the differing ED timeline statements.
- Whether clinical-study results are peer-reviewed, validated in larger real-world populations, and sufficient to support regulatory and commercial claims.
- Whether reimbursement arrangements, physician adoption, pricing, manufacturing scale, and product economics can support a viable business.
- Progress in remediating internal-control material weaknesses and the potential for additional equity issuance or dilution from warrants, options, and future financing.